SeaStar Medical Q2 FY26 net loss widens to $3.7 million; revenue rises 82% to $0.6 million

Reuters2026/08/12 20:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SeaStar Medical posted Q2 net loss of USD 3.7 million, or USD 0.91 per share, widening from a year earlier.
Net revenue rose 82% year over year to USD 615,000, driven by higher QUELIMMUNE demand and three new children’s hospital customers.
Gross margin slipped 1 percentage point to 91%, while RD expense climbed to USD 2.52 million on higher trial costs.
Cash fell to USD 7 million at June 30 from USD 12 million at year-end 2025.
NEUTRALIZE-AKI adult trial reached 223 of 339 patients; enrollment completion targeted around year-end or Q1 2027, with PMA filing eyed near end-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808869) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SeaStar Medical Q2 FY26 net loss widens to $3.7 million; revenue rises 82% to $0.6 million

You may also like

Crypto prices